Reliable Biopharmaceutical Corporation: Med Opportunity Partners completed the buyout of Reliable in October 2007. Reliable is a St Louis based developer and manufacturer of active pharmaceutical ingredients (APIs) and high purity pharmaceutical processing chemicals. Reliable’s products are the active ingredients for leading generic injectable drugs. The company also has sophisticated API research and development along with manufacturing capability of complex drug molecules to deliver customized solutions for leading generic, branded pharmaceutical and biotechnology companies.

Transaction Rationale:

• Strong customer relationships with leading generic injectable companies as well as leading pharmaceutical and biotechnology companies, 2007. Supplier of Year for Eli Lilly
• Sophisticated research and development capabilities
• Growing portfolio and pipeline of active materials for oncology, cardiovascular, neurological and pain drugs
• Proven highly profitable business model and attractive purchase multiple
• Experienced management team
• Opportunity to benefit from huge market of injectable drugs coming off patent, including biologic drugs

Creating Value:

• Accelerated growth through expansion of sales force
• Developed a robust pipeline focused on target complex molecules
• Enhanced the management team
• Invested in capacity expansion